What's in Supernus Pharmaceuticals, Inc.'s pipeline?

Supernus Pharmaceuticals, Inc. has 25 drugs in our index: 5 marketed, 0 filed, 4 in Phase 3, 4 in Phase 2, 12 in Phase 1.

Which companies overlap with Supernus Pharmaceuticals, Inc.'s portfolio?

Top competitors by shared drug class: Acerta Pharma BV, AstraZeneca, Avidity Biosciences, Inc., Eli Lilly and Company, Hoffmann-La Roche.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/supernus-pharmaceuticals-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-06-10 · How we verify

Supernus Pharmaceuticals, Inc. — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Supernus Pharmaceuticals, Inc. pipeline: 5 marketed, 0 filed, 4 Phase 3, 4 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

5 marketed 0 filed 4 Phase 3 4 Phase 2 12 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
SPN-812 (600mg, QD)	SPN-812 (600mg, QD)	marketed	Selective norepinephrine reuptake inhibitor (NRI)	Norepinephrine transporter (NET)	Psychiatry / Neurology
SPN-812	SPN-812	marketed			Other
MYOBLOC	MYOBLOC	marketed	Botulinum toxin type B	VAMP/synaptobrevin (SNARE protein)	Neurology
SPN-538	SPN-538	marketed			Other
ZULRESSO®	ZULRESSO®	marketed	Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive Modulator	GABA-A receptor alpha-1/beta-2/gamma-2	Neuroscience
Oxcarbazepine XR	Oxcarbazepine XR	phase 3	Anticonvulsant; voltage-gated sodium channel blocker	Voltage-gated sodium channels	Neurology
SPN-810 (18 mg)	SPN-810 (18 mg)	phase 3	5-HT1A receptor agonist	5-HT1A receptor	Psychiatry/Neurology
SPN-810 (36 mg)	SPN-810 (36 mg)	phase 3	mood stabilizer		Psychiatry
SAGE-547	SAGE-547	phase 3	antisense oligonucleotide	GABA_A receptor alpha 1 subunit	Neurology

Therapeutic area mix

Neurology · 3
Other · 2
Neuroscience · 1
Psychiatry · 1
Psychiatry / Neurology · 1
Psychiatry/Neurology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Acerta Pharma BV · 1 shared drug class
AstraZeneca · 1 shared drug class
Avidity Biosciences, Inc. · 1 shared drug class
Eli Lilly and Company · 1 shared drug class
Hoffmann-La Roche · 1 shared drug class
Ionis Pharmaceuticals, Inc. · 1 shared drug class
Massachusetts General Hospital · 1 shared drug class
Par Pharmaceutical, Inc. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Supernus Pharmaceuticals, Inc.:

Cite this brief

Drug Landscape (2026). Supernus Pharmaceuticals, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/supernus-pharmaceuticals-inc. Accessed 2026-06-10.